Table 3. Univariate Analysis Results Between Patients With and Without Sustained Virological Response (SVR).
| SVR | Non SVR | P value | |
| Age, y (= 40), No. (%) | 27 (54) | 14 (28) | 0.008 a |
| Sex, (male), No. (%) | 40 (80) | 38 (76) | 0.629 a |
| BMI (kg/m2) ( > 25), No. (%) | 18 (36) | 14 (28) | 0.391 a |
| HCV risk factor (IVDU), No. (%) | 15 (30) | 18 (36) | 0.523 a |
| Previous treatment (non-responder) No. (%) | 7 (14) | 18 (36) | 0.011 a |
| Genotype (1a), No. (%) | 29 (41) | 41 (57) | 0.009 a |
| HCV RNA (< 600 000 IU/ml), No. (%) | 25 (50) | 16 (32) | 0.067 a |
| WBC,mm3, mean ± SD | 6 164 ± 1 926 | 5 890 ± 1 820 | 0.467 b |
| PMN,mm3, mean ± SD | 3 441 ± 1 297 | 3 272 ± 1 357 | 0.527 b |
| Hb, g/dl, mean ± SD | 14.8 ± 1.7 | 14.4 ± 1.8 | 0.308 b |
| PLT ,mm3, mean ± SD | 196 020 ± 73 984 | 180 700 ± 67 382 | 0.282 b |
| AST (= 40 U/L), No. (%) | 34 (68) | 30 (60) | 0.405 a |
| ALT (= 40 U/L), No. (%) | 38 (76) | 36 (72) | 0.648 a |
| AST/ALT > 1, No. (%) | 16 (32) | 11 (22) | 0.260 a |
| APRI = 1.5, No. (%) | 43 (52) | 40 (48) | 0.424 a |
| End of treatment leukopenia c , No. (%) | 26 (52) | 25 (50) | 0.841 a |
| End of treatment neutropenia d , No. (%) | 3 (6) | 2 (4) | 0.716 a |
| End of treatment thrombocytopenia e , No. (%) | 9 (18) | 10 (20) | 0.761 a |
Abbreviations: ALT, alanine aminotransferase; APRI, aspartate aminotransferase (AST) to platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; Hb, hemoglobin; IVDU, intravenous drug user; PLT, platelets; PMN, polymorphoneuclear cells; WBC, white blood cells
aChi square test
bIndependent sample t test
cEnd of treatment leukopenia: WBC < 3000/mm3
dEnd of treatment neutropenia: PMN < 750/mm3
eEnd of treatment thrombocytopenia: platelet < 100 000/mm3